Long-term safety follow-up of GT005 gene therapy in age-related macular degeneration
Follows people with geographic atrophy from macular degeneration treated earlier with GT005 gene therapy.
Plain-language title generated from the registry record
Registry title: ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Key facts
- Where
- London and Sunderland, United KingdomSee the 2 sites
- Phase
- Phase 2
Where in United Kingdom
- The Retina Clinic LondonLondon, United KingdomNo longer taking part
- South Tyneside and Sunderland NHS Foundation Trust - Sunderland Eye InfirmarySunderland, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gyroscope Therapeutics Limited
- Trial code
- NCT05481827EU 2024-510946-15-00
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.Read full original descriptionShow less
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
Inclusion: Able and willing to give written informed consent; Received GT005 in an antecedent study, GT005-01 (FOCUS, NCT03846193), GT005-02 (EXPLORE, NCT04437368) and GT005-03 (HORIZON, NCT04566445); Willing to attend study visits and complete the study procedures.